Cover Image
市場調查報告書

生物醫藥品的全球市場:分析與預測

Global Biopharmaceutical Market Report & Forecast (2018-2023)

出版商 IMARC Services Pvt. Ltd. 商品編碼 367470
出版日期 內容資訊 英文 210 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物醫藥品的全球市場:分析與預測 Global Biopharmaceutical Market Report & Forecast (2018-2023)
出版日期: 2018年02月04日 內容資訊: 英文 210 Pages
簡介

本報告提供全球生物醫藥品的市場相關分析,整體市場規模的成果值、預測值,及各地區及各症狀、各類藥物的詳細趨勢,主要企業簡介與業績,代表性產品的概要銷售業績、預測,產業整體競爭力 (SWOT分析) 的資訊彙整,為您概述為以下內容。

第1章 序章

第2章 市場定義和分析方法

第3章 摘要整理

第4章 簡介

第5章 全球生物醫藥品市場

  • 市場的成果與預測
  • 各地區市場
  • 各適應症的市場
    • 自體免疫疾病
    • 腫瘤
    • 代謝障礙
    • 其他
  • 各類藥物的市場
    • 基因改造蛋白質
    • 單株抗體
    • 純化蛋白質
  • 競爭環境
    • 大生物醫藥品企業
    • 代表性生物醫藥品
  • 價值鏈分析
  • 波特的五力分析

第6章 北美

  • 美國
  • 加拿大

第7章 南美

  • 墨西哥
  • 巴西
  • 阿根廷

第8章 歐洲

  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 俄羅斯
  • 土耳其

第9章 亞太地區

  • 日本
  • 中國
  • 澳洲
  • 韓國
  • 印度

第10章 SWOT分析

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: SR1018B13_Report

The global biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in 1982. Today hundreds of biopharmaceuticals have already been approved and many more are in late stages of clinical development. These drugs have not only advanced the prevention and treatment of a number of life threatening diseases but have also provided the thrust for the continued success of the pharmaceutical industry.

Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a biopharmaceutical, however, represents a very risky proposition as out of every ten drugs that enter the clinical phases, only three manage to gain market approval. But the industry's multibillion dollar revenues and strong growth rates in previous years bears a testimony to the fact that the ones that finally do get approval represent goldmines for investors.

Although factors like biosimilar entry and cost containment in the developed markets are likely to restrain the growth of this market in the coming years, IMARC expects that with their high potency and ability to attack targets beyond the reach of traditional small molecule drugs, biopharmaceuticals provide the industry with a huge scope for future growth. A rich late stage pipeline and increasing demand in emerging markets are also expected to be major drivers in the coming years.

The study covers the market analysis of various segments and sub-segments of the biopharmaceutical industry based on class and key indicative areas. Recombinant proteins currently represent the biggest segment on the basis of class accounting for the majority of the global biopharmaceutical sales. Recombinant proteins are followed by monoclonal antibodies and purified proteins. On the basis of key indicative and therapeutic application areas for biopharmaceuticals, autoimmune diseases represent the largest segment followed by oncology. With most of the current and future monoclonal antibodies targeted against autoimmune diseases such as rheumatoid arthritis and oncology, autoimmune diseases and oncology will continue to represent the dominant indications for biopharmaceuticals over the next five years.

The biopharmaceutical market is largely dominated by the US accounting for nearly half of the total global sales. The other top markets include Germany, Japan, France, Italy, Spain, UK and Canada. Moreover, increasing disposable incomes and a larger access to healthcare insurance, the market for biopharmaceuticals is also expected to expand and offer great opportunities and growth prospects across various emerging markets over the next few years. The report has also provided a robust analysis of the key players operating in the global biopharmaceutical market. Some of the key players analysed in this report include: Roche, Amgen, Novo Nordisk, AbbVie and Sanofi.

IMARC's new report "Global Biopharmaceutical Market Report & Forecast (2018-2023)" gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2023. This report will serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in any form.

What We Have Achieved in this Report?

Deep Qualitative Understanding of Various Factors Driving and Restraining the Global Biopharmaceutical Market

Key Aspects Analyzed:

  • Driving Factors
  • Restraining Factors
  • Market Opportunities
  • Threats
  • Comprehensive Situation Analysis of the Global Biopharmaceutical Market and its Dynamics

Regions/Countries Covered:

  • North America: United States and Canada
  • Latin America: Mexico, Brazil and Argentina
  • Europe: Germany, France, Italy, Spain, United Kingdom, Russia and Turkey
  • Asia Pacific: Japan, China, Australia, South Korea, India and Indonesia
  • Classes Covered for Each Country: Erythropoietins, Insulin, Interferons, Growth Hormones, Immunoglobulins, Colony Stimulating Factors, Recombinant Blood Factors, Recombinant Enzymes, Growth Factors, Interleukins, Monoclonal Antibodies and Purified Proteins

Focus of the Analysis for Each Country:

  • Total Market Performance
  • Performance of Various Classes
  • Performance of Top Players
  • Market Forecast

Key Questions Answered in this Report:

  • What are the key advantages/ disadvantages of biopharmaceuticals over small molecule drugs in terms of efficacy, safety, price, approval times, market growth, etc.?
  • What are the key opportunities and threats faced by the biopharmaceutical industry?
  • What has been the historical and current performance of the global biopharmaceutical market and how is it expected to perform in the coming years?
  • Which are the world's largest biopharmaceutical markets?
  • Which are the world's fastest growing biopharmaceutical markets?
  • What is the structure and composition of various biopharmaceutical markets across the globe?
  • Which are the world's largest biopharmaceutical segments?
  • Which are the world's fastest growing biopharmaceutical segments?
  • Who are the world's largest biopharmaceutical companies and how have they performed in recent years?

Table of Contents

1. Preface

2. Research Methodology and Market Definitions

3. Executive Summary

4. Introduction

5. Global Biopharmaceutical Market

  • 5.1. Market Performance and Forecast
    • 5.1.1. Current Performance (2010-2017)
    • 5.1.2. Market Forecast (2018-2023)
  • 5.2. Market by Region
    • 5.2.1. Current Performance (2010-2017)
    • 5.2.2. Market Forecast (2018-2023)
  • 5.3. Market by Indication
    • 5.3.1. Autoimmune Diseases
    • 5.3.2. Oncology
    • 5.3.3. Metabolic Disorders
    • 5.3.4. Others
  • 5.4. Market by Class
    • 5.4.1. Recombinant Proteins
      • 5.4.1.1. Current Performance (2010-2017)
      • 5.4.1.2. Market Forecast (2018-2023)
    • 5.4.2. Monoclonal Antibodies
      • 5.4.2.1. Current Performance (2010-2017)
      • 5.4.2.2. Market Forecast (2018-2023)
    • 5.4.3. Purified Proteins
      • 5.4.3.1. Current Performance (2010-2017)
      • 5.4.3.2. Market Forecast (2018-2023)
  • 5.5. Competitive Landscape
    • 5.5.1. Top Biopharmaceutical Players
    • 5.5.2. Top Biopharmaceutical Drugs
  • 5.6. Value Chain Analysis
  • 5.7. Porter's Five Forces Analysis
    • 5.7.1. Overview
    • 5.7.2. Bargaining Power of Buyers
    • 5.7.3. Bargaining Power of Suppliers
    • 5.7.4. Degree of Rivalry
    • 5.7.5. Threat of New Entrants
    • 5.7.6. Threat of Substitutes

6. North America

  • 6.1. United States
    • 6.1.1. Market Performance (2010-2017)
    • 6.1.2. Market by Class
      • 6.1.2.1. Recombinant Proteins
      • 6.1.2.2. Monoclonal Antibodies
      • 6.1.2.3. Purified Proteins
    • 6.1.3. Top Players
    • 6.1.4. Market Forecast (2018-2023)
  • 6.2. Canada
    • 6.2.1. Market Performance (2010-2017)
    • 6.2.2. Market by Class
      • 6.2.2.1. Recombinant Proteins
      • 6.2.2.2. Monoclonal Antibodies
      • 6.2.2.3. Purified Proteins
    • 6.2.3. Top Players
    • 6.2.4. Market Forecast (2018-2023)

7. Latin America

  • 7.1. Mexico
    • 7.1.1. Market Performance (2010-2017)
    • 7.1.2. Market by Class
      • 7.1.2.1. Recombinant Proteins
      • 7.1.2.2. Monoclonal Antibodies
      • 7.1.2.3. Purified Proteins
    • 7.1.3. Top Players
    • 7.1.4. Market Forecast (2018-2023)
  • 7.2. Brazil
    • 7.2.1. Market Performance (2010-2017)
    • 7.2.2. Market by Class
      • 7.2.2.1. Recombinant Proteins
      • 7.2.2.2. Monoclonal Antibodies
      • 7.2.2.3. Purified Proteins
    • 7.2.3. Top Players
    • 7.2.4. Market Forecast (2018-2023)
  • 7.3. Argentina
    • 7.3.1. Market Performance (2010-2017)
    • 7.3.2. Market by Class
      • 7.3.2.1. Recombinant Proteins
      • 7.3.2.2. Monoclonal Antibodies
      • 7.3.2.3. Purified Proteins
    • 7.3.3. Top Players
    • 7.3.4. Market Forecast (2018-2023)

8. Europe

  • 8.1. Germany
    • 8.1.1. Market Performance (2010-2017)
    • 8.1.2. Market by Class
      • 8.1.2.1. Recombinant Proteins
      • 8.1.2.2. Monoclonal Antibodies
      • 8.1.2.3. Purified Proteins
    • 8.1.3. Top Players
    • 8.1.4. Market Forecast (2018-2023)
  • 8.2. France
    • 8.2.1. Market Performance (2010-2017)
    • 8.2.2. Market by Class
      • 8.2.2.1. Recombinant Proteins
      • 8.2.2.2. Monoclonal Antibodies
      • 8.2.2.3. Purified Proteins
    • 8.2.3. Top Players
    • 8.2.4. Market Forecast (2018-2023)
  • 8.3. Italy
    • 8.3.1. Market Performance (2010-2017)
    • 8.3.2. Market by Class
      • 8.3.2.1. Recombinant Proteins
      • 8.3.2.2. Monoclonal Antibodies
      • 8.3.2.3. Purified Proteins
    • 8.3.3. Top Players
    • 8.3.4. Market Forecast (2018-2023)
  • 8.4. Spain
    • 8.4.1. Market Performance (2010-2017)
    • 8.4.2. Market by Class
      • 8.4.2.1. Recombinant Proteins
      • 8.4.2.2. Monoclonal Antibodies
      • 8.4.2.3. Purified Proteins
    • 8.4.3. Top Players
    • 8.4.4. Market Forecast (2018-2023)
  • 8.5. United Kingdom
    • 8.5.1. Market Performance (2010-2017)
    • 8.5.2. Market by Class
      • 8.5.2.1. Recombinant Proteins
      • 8.5.2.2. Monoclonal Antibodies
      • 8.5.2.3. Purified Proteins
    • 8.5.3. Top Players
    • 8.5.4. Market Forecast (2018-2023)
  • 8.6. Russia
    • 8.6.1. Market Performance (2010-2017)
    • 8.6.2. Market by Class
      • 8.6.2.1. Recombinant Proteins
      • 8.6.2.2. Monoclonal Antibodies
      • 8.6.2.3. Purified Proteins
    • 8.6.3. Top Players
    • 8.6.4. Market Forecast (2018-2023)
  • 8.7. Turkey
    • 8.7.1. Market Performance (2010-2017)
    • 8.7.2. Market by Class
      • 8.7.2.1. Recombinant Proteins
      • 8.7.2.2. Monoclonal Antibodies
      • 8.7.2.3. Purified Proteins
    • 8.7.3. Top Players
    • 8.7.4. Market Forecast (2018-2023)

9. Asia Pacific

  • 9.1. Japan
    • 9.1.1. Market Performance (2010-2017)
    • 9.1.2. Market by Class
      • 9.1.2.1. Recombinant Proteins
      • 9.1.2.2. Monoclonal Antibodies
      • 9.1.2.3. Purified Proteins
    • 9.1.3. Top Players
    • 9.1.4. Market Forecast (2018-2023)
  • 9.2. China
    • 9.2.1. Market Performance (2010-2017)
    • 9.2.2. Market by Class
      • 9.2.2.1. Recombinant Proteins
      • 9.2.2.2. Monoclonal Antibodies
      • 9.2.2.3. Purified Proteins
    • 9.2.3. Top Players
    • 9.2.4. Market Forecast (2018-2023)
  • 9.3. Australia
    • 9.3.1. Market Performance (2010-2017)
    • 9.3.2. Market by Class
      • 9.3.2.1. Recombinant Proteins
      • 9.3.2.2. Monoclonal Antibodies
      • 9.3.2.3. Purified Proteins
    • 9.3.3. Top Players
    • 9.3.4. Market Forecast (2018-2023)
  • 9.4. South Korea
    • 9.4.1. Market Performance (2010-2017)
    • 9.4.2. Market by Class
      • 9.4.2.1. Recombinant Proteins
      • 9.4.2.2. Monoclonal Antibodies
      • 9.4.2.3. Purified Proteins
    • 9.4.3. Top Players
    • 9.4.4. Market Forecast (2018-2023)
  • 9.5. India
    • 9.5.1. Market Performance (2010-2017)
    • 9.5.2. Market by Class
      • 9.5.2.1. Recombinant Proteins
      • 9.5.2.2. Monoclonal Antibodies
      • 9.5.2.3. Purified Proteins
    • 9.5.3. Top Players
    • 9.5.4. Market Forecast (2018-2023)
  • 9.6. Indonesia
    • 9.6.1. Market Performance (2010-2017)
    • 9.6.2. Market by Class
      • 9.6.2.1. Recombinant Proteins
      • 9.6.2.2. Monoclonal Antibodies
      • 9.6.2.3. Purified Proteins
    • 9.6.3. Top Players
    • 9.6.4. Market Forecast (2018-2023)

10. SWOT Analysis

  • 10.1. Strengths
  • 10.2. Weaknesses
  • 10.3. Opportunities
  • 10.4. Threats

List of Figures

  • Figure 1: Global Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 2: Complexity of Biopharmaceuticals
  • Figure 3: Sources of Biopharmaceuticals
  • Figure 4: Global: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 5: Global: Biopharmaceutical Market Forecast: Value trends (in Million US$), 2018-2023
  • Figure 6: Global: Biopharmaceutical Market: Sales Share by Country (in %), 2017
  • Figure 7: Global: Biopharmaceutical Market Forecast: Sales Share by Country (in %), 2023
  • Figure 8: Global: Biopharmaceutical Market: Sales Share by Indication (in %), 2017
  • Figure 9: Global: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 10: Global: Biopharmaceutical Market Forecast: Sales by Class (in Million US$), 2018-2023
  • Figure 11: Global: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 12: Global: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 13: Global: Recombinant Proteins Market Forecast (in Million US$), 2018-2023
  • Figure 14: Global: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 15: Global: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 16: Global: Monoclonal Antibodies Market Forecast (in Million US$), 2018-2023
  • Figure 17: Global: Purified Proteins Market (in Million US$), 2010-2017
  • Figure 18: Global: Purified Proteins Market: Sales Share by Class (in %), 2017
  • Figure 19: Global: Purified Proteins Market Forecast (in Million US$), 202-2023
  • Figure 20: Global: Biopharmaceutical Market: Sales Share of Top Biopharmaceuticals (in %),
  • Figure 21: Global: Biopharmaceutical Industry: Value Chain Analysis
  • Figure 22: Biopharmaceutical Industry: Porter's Five Forces Analysis
  • Figure 23: United States: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 24: United States: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 25: United States: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 26: United States: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 27: United States: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 28: United States: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 29: United States: Purified Proteins Market (in Million US$), 2010-2017
  • Figure 30: United States: Purified Proteins Market: Sales Share by Class (in %), 2017
  • Figure 31: United States: Biopharmaceutical Market: Sales Share of Top Players (in %), 2017
  • Figure 32: United States: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 33: United States: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 34: Canada: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 35: Canada: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 36: Canada: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 37: Canada: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 38: Canada: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 39: Canada: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 40: Canada: Biopharmaceutical Market: Sales Share of Top Players (in %), 2017
  • Figure 41: Canada: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 42: Canada: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 43: Mexico: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 44: Mexico: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 45: Mexico: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 46: Mexico: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 47: Mexico: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 48: Mexico: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 49: Mexico: Purified Proteins Market (in '000 US$), 2010-2017
  • Figure 50: Mexico: Biopharmaceutical Market: Sales Share of Top Players (in %), 2017
  • Figure 51: Mexico: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 52: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 53: Brazil: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 54: Brazil: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 55: Brazil: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 56: Brazil: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 57: Brazil: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 58: Brazil: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 59: Brazil: Purified Proteins Market (in Million US$), 2010-2017
  • Figure 60: Brazil: Biopharmaceutical Market: Sales Share of Top Players (in %), 2017
  • Figure 61: Brazil: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 62: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 63: Argentina: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 64: Argentina: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 65: Argentina: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 66: Argentina: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 67: Argentina: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 68: Argentina: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 69: Argentina: Purified Proteins Market (in Million US$), 2010-2017
  • Figure 70: Argentina: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 71: Argentina: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 72: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 73: Germany: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 74: Germany: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 75: Germany: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 76: Germany: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 77: Germany: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 78: Germany: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 79: Germany: Purified Proteins Market (in Million US$), 2010-2017
  • Figure 80: Germany: Purified Proteins Market: Sales Share by Class (in %), 2017
  • Figure 81: Germany: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 82: Germany: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 83: Germany: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 84: France: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 85: France: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 86: France: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 87: France: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 88: France: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 89: France: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 90: France: Purified Proteins Market (in Million US$), 2010-2017
  • Figure 91: France: Biopharmaceutical Market: Sales Share of Top Players (in %), 2017
  • Figure 92: France: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 93: France: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 94: Italy: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 95: Italy: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 96: Italy: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 97: Italy: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 98: Italy: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 99: Italy: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 100: Italy: Purified Proteins Market (in Million US$), 2010-2017
  • Figure 101: Italy: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 102: Italy: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 103: Italy: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 104: Spain: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 105: Spain: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 106: Spain: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 107: Spain: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 108: Spain: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 109: Spain: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 110: Spain: Purified Proteins Market (in Million US$), 2010-2017
  • Figure 111: Spain: Purified Proteins Market: Sales Share by Class (in %), 2017
  • Figure 112: Spain: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 113: Spain: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 114: Spain: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 115: UK: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 116: UK: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 117: UK: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 118: UK: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 119: UK: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 120: UK: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 121: UK: Purified Proteins Market (in Million US$), 2010-2017
  • Figure 122: UK: Purified Proteins Market: Sales Share by Class (in %), 2017
  • Figure 123: UK: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 124: UK: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 125: UK: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 126: Russia: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 127: Russia: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 128: Russia: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 129: Russia: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 130: Russia: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 131: Russia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 132: Russia: Purified Proteins Market : (in Million US$), 2010-2017
  • Figure 133: Russia: Purified Proteins Market: Sales Share by Class (in %), 2017
  • Figure 134: Russia: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 135: Russia: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 136: Russia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 137: Turkey: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 138: Turkey: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 139: Turkey: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 140: Turkey: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 141: Turkey: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 142: Turkey: Purified Proteins Market (in Million US$), 2010-2017
  • Figure 143: Turkey: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 144: Turkey: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 145: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 146: Japan: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 147: Japan: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 148: Japan: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 149: Japan: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 150: Japan: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 151: Japan: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 152: Japan: Purified Proteins Market (in Million US$), 2010-2017
  • Figure 153: Japan: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 154: Japan: Biopharmaceutical Market Forecast : Value trend(in Million US$), 2018-2023
  • Figure 155: Japan: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 156: China: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 157: China: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 158: China: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 159: China: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 160: China: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 161: China: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 162: China: Purified Proteins Market : (in Million US$), 2010-2017
  • Figure 163: China: Purified Proteins Market: Sales Share by Class (in %), 2017
  • Figure 164: China: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 165: China: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 166: China: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 167: Australia: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 168: Australia: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 169: Australia: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 170: Australia: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 171: Australia: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 172: Australia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 173: Australia: Purified Proteins Market (in Million US$), 2010-2017
  • Figure 174: Australia: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 175: Australia: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 176: Australia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 177: South Korea: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 178: South Korea: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 179: South Korea: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 180: South Korea: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 181: South Korea: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 182: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2017
  • Figure 183: South Korea: Purified Proteins Market (in Million US$), 2010-2017
  • Figure 184: South Korea: Purified Proteins Market: Sales Share by Class (in %), 2017
  • Figure 185: South Korea: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 186: South Korea: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 187: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 188: India: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 189: India: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 190: India: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 191: India: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 192: India: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 193: India: Purified Proteins Market (in Million US$), 2010-2017
  • Figure 194: India: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 195: India: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 196: India: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 197: Indonesia: Biopharmaceutical Market (in Million US$), 2010-2017
  • Figure 198: Indonesia: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
  • Figure 199: Indonesia: Recombinant Proteins Market (in Million US$), 2010-2017
  • Figure 200: Indonesia: Recombinant Proteins Market: Sales Share by Class (in %), 2017
  • Figure 201: Indonesia: Monoclonal Antibodies Market (in Million US$), 2010-2017
  • Figure 202: Indonesia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
  • Figure 203: Indonesia: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 204: Indonesia: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
  • Figure 205: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
  • Figure 206: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2001 & 2017
  • Figure 207: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products
  • Figure 208: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used
  • Figure 209: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %)
  • Figure 210: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs (in US$)
  • Figure 211: Emerging Biopharmaceutical Market Forecast (in Million US$), 2017 & 2023
  • Figure 212: Developed Biopharmaceutical Market Forecast (in Million US$), 2017 & 2023
  • Figure 213: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in Numbers), 2002-2017
  • Figure 214: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs (in Million US$)
  • Figure 215: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months)

List of Tables

  • Table 1: Global: Biopharmaceutical Market: Definition & Segmentation
  • Table 2: Global: Biopharmaceutical Market: SWOT Analysis
  • Table 3: Global: Biopharmaceutical Market Forecast: Sales by Region (In Million US$), 2017 & 2023
  • Table 4: Differences Between Small Molecule Drugs & Biopharmaceuticals
  • Table 5: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs
  • Table 6: Global: Biopharmaceutical Market: Sales by Country (in Million US$), 2010-2017
  • Table 7: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million US$), 2018-2023
  • Table 8: Global: Biopharmaceutical Market: Sales by Indication (in Billion US$), 2017
  • Table 9: Mode of Administration of Popular Biotech Drugs
Back to Top